Team:Hong Kong HKUST/hp/interview/yu

From 2013.igem.org

(Difference between revisions)
 
(14 intermediate revisions not shown)
Line 69: Line 69:
{visibility:hidden;}
{visibility:hidden;}
#globalWrapper
#globalWrapper
-
{position: relative;font-size:127%;width:100%;margin:0;padding:0;padding-bottom:10px;background-color:#494042;height:1750px;}
+
{position: relative;font-size:127%;width:100%;margin:0;padding:0;padding-bottom:10px;background-color:#494042;height:1350px;}
#content
#content
-
{width: 995px;background-color:#Ffffff;height:1700px;padding:0px;margin-top:0px;line-height: 1.5em;color: black;}
+
{width: 995px;border:none;background-color:#ffffff;height:1300px;padding:0px;margin-top:0px;line-height: 1.5em;color: black;}
#top-section
#top-section
{height:2px;border:none;background-color:#494042;}
{height:2px;border:none;background-color:#494042;}
Line 167: Line 167:
top:141px;
top:141px;
width:100%;
width:100%;
 +
z-index:1;
}
}
#back-top {
#back-top {
Line 172: Line 173:
top: 10%;
top: 10%;
right: 2%;
right: 2%;
 +
z-index:16;
}
}
#back-top a {
#back-top a {
Line 239: Line 241:
width: 83.33333%;
width: 83.33333%;
top:192px;
top:192px;
-
z-index:-2;
+
 
}
}
.column, .columns {
.column, .columns {
Line 294: Line 296:
margin-left: 20px;
margin-left: 20px;
margin-bottom: 0;}
margin-bottom: 0;}
 +
#msk1{margin-left:20px;}
 +
#msk2{margin-left:55px;}
 +
#msk3{margin-left:35px;}
 +
#msk4{margin-left:70px;}
 +
 +
#iGEM_Logo{
 +
width:100px;
 +
height:80px;
 +
position:absolute;
 +
right:10px;
 +
top:60px;
 +
z-index:+15;
 +
}
 +
#hkust_Logo{
 +
width:60px;
 +
height:80px;
 +
position:absolute;
 +
right:110px;
 +
top:60px;
 +
z-index:+15;
 +
}
 +
 +
</style>
</style>
-
</head>
+
 
<body>
<body>
-
<p id="back-top" style=""display:none;>
+
 
 +
 
 +
          <a href="https://2013.igem.org/Main_Page"><img id="iGEM_Logo" src="https://static.igem.org/mediawiki/2013/4/46/Igem_qgem_logo.png"></a>
 +
         
 +
 
 +
<a href="http://www.ust.hk/eng/index.htm"><img id="hkust_Logo" src="https://static.igem.org/mediawiki/2013/5/55/Hkust_logo.gif"></a>
 +
 
 +
 
 +
<p id="back-top" style="display:none;">
<a href="#top"><span><img src="http://515alive.com/theme/img/up-arrow.png" style="width:90%;"><br><br>BACK TO TOP</span></a>
<a href="#top"><span><img src="http://515alive.com/theme/img/up-arrow.png" style="width:90%;"><br><br>BACK TO TOP</span></a>
</p>
</p>
Line 321: Line 354:
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/abstract">Abstract</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/abstract">Abstract</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modules">Modules Description</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modules">Modules Description</a></li>
 +
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/data">Data Page</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/Parts">Parts</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/Parts">Parts</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/characterization">Characterization</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/characterization">Characterization</a></li>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/modelling">Modeling</a></li>
 
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/results">Result</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/results">Result</a></li>
 +
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/future">Future Work</a></li>
</ul>
</ul>
</li>
</li>
Line 333: Line 367:
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/protocols">Protocols</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/protocols">Protocols</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/safety">Safety</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/safety">Safety</a></li>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/future">Future Work</a></li>
+
 
</ul>
</ul>
</li>
</li>
Line 346: Line 380:
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp">Human Practice</a>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp">Human Practice</a>
<ul>
<ul>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview">Interviews</a></li>
 
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/cp">Country Profile</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/cp">Country Profile</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/blog">Blog</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/blog">Blog</a></li>
-
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/article">Article</a></li>
+
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview">Interviews</a></li>
 +
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/article/genet">Article</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/video">Videos</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/video">Videos</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/presentation">Presentations</a></li>
<li><a href="https://2013.igem.org/Team:Hong_Kong_HKUST/hp/presentation">Presentations</a></li>
Line 357: Line 391:
</ul>
</ul>
-
</div>
 
</div>
</div>
       <div class="row">
       <div class="row">
-
<div class="two columns">
+
<div class="two columns"><br>
-
<ul class="side-nav">
+
<ul class="side-nav">
<li>
<li>
-
<h6>Prof. Albert Yu</h6>
+
<h6>Interview</h6>
</li>
</li>
<li class="divider"></li>
<li class="divider"></li>
<li>
<li>
 +
Prof. Albert Yu<ul><li>
<a href=#1>Introduction</a>
<a href=#1>Introduction</a>
</li>
</li>
Line 374: Line 408:
<li>
<li>
<a href=#3>Conclusion</a>
<a href=#3>Conclusion</a>
-
</li>
 
-
<li>
 
-
<a href=#4>Interview Video</a>
 
</li>
</li>
<li>
<li>
<a href=#5>Pictures</a>
<a href=#5>Pictures</a>
 +
</li><li>
 +
<a href=#6>Download Links</a>
</li>
</li>
-
 
+
</ul>
-
 
+
-
+
-
</ul>
+
-
 
+
-
<ul class="side-nav1">
+
-
<li>
+
-
<h6>Interview</h6>
+
-
</li>
+
-
<li class="divider"></li>
+
-
<li>
+
-
Prof. Albert Yu
+
</li>
</li>
<li>
<li>
Line 410: Line 432:
<div class="nine columns"><p id="1"></p>
<div class="nine columns"><p id="1"></p>
<h3>Overview</h3>
<h3>Overview</h3>
-
Professor Albert Yu is the chairman of the Hong Kong Biotechnology Organization (HK BIO), and also a professor of the Department of Neurobiology in Pecking University, China. As an entrepreneur and a scientist, Professor Yu gave us realistic insight of our project. Meeting Professor Albert Yu helped us to evaluate our project beyond the laboratory environment and to think about the possible future application as a biotechnology product. Towards the end of the interview, we have also talked about the bio-ethics and bio-safety issues regarding synthetic biology.  
+
Professor Albert Yu is the chairman of the Hong Kong Biotechnology Organization (HKBIO), and also a professor of the Department of Neurobiology of Peking University, China. As an entrepreneur and a scientist, Prof. Yu gave us realistic insights to our project. Meeting Prof. Yu helped us to evaluate our project beyond the laboratory environment and to think about its possible future application as a biotechnology product. Towards the end of the interview, we also talked about the bioethics and biosafety issues regarding synthetic biology.  
<br>
<br>
</div>
</div>
Line 419: Line 441:
<h3>Main Discussion</h3>
<h3>Main Discussion</h3>
-
Professor Yu mentioned that our project is a small step and that we have a long way to go to apply our project as commercial biotechnology product. He told us that because we are trying to insert genes into a human body, we need to be very careful with concluding how our project could be realistically applied in the future. Inserting genes into a human body can create novel metabolism that can cause side effects. Also, because the general public considers obesity less harmful, people might be reluctant to use an invasive product if they believe a less invasive means such as exercising can solve the problem. He also encouraged us to look into other plant genes that could be used to cure fatal diseases.<br><br>  
+
Prof. Yu mentioned that our project is a small step and that we have a long way to go to apply our project as a commercial biotechnology product. He told us that because we are trying to insert genes into a human body, we need to be very careful with concluding how our project could be realistically applied in the future. Inserting genes into a human body can create novel metabolism properties that could lead to side effects. Also, because the general public considers obesity less harmful, people might be reluctant to sign up for invasive treatment if they believe a less invasive means such as exercising can solve the problem. He also encouraged us to look into other plant genes that could be used to cure fatal diseases.<br><br>  
-
We have also discussed about issues on bio-safety and bio-ethics. Professor Yu said that we need to be responsible scientists and utilize the research to improve human life. He also mentioned to produce a bio-product, it is very important to consider the ethical issues of the project from the very start.
+
We also discussed about issues on biosafety and bioethics. Prof. Yu said that we need to be responsible scientists and utilize research to improve human life. He also mentioned that to produce a bioproduct, it is very important to consider the ethical issues of the project from the very start.
<br>
<br>
   
   
Line 429: Line 451:
<h3>Conclusion</h3>
<h3>Conclusion</h3>
-
The interview with Professor Albert Yu helped us to have a realistic view of our project. The interview also showed that more in-depth consideration of our project’s future application is necessary if we want to see are project utilized a safe bio-product.<br>
+
The interview with Professor Albert Yu helped us to realize the social environment our project would encounter, and the barriers that come with it. The interview also showed that more in-depth consideration of our project’s future application is necessary if we want to see it utilized as a safe bioproduct.<br>
</div>
</div>
</div>
</div>
-
<div class="row">
 
-
<div class="nine columns"><p id="4"></p>
 
-
<h3>Interview Video</h3>
 
-
<br>
 
-
<center><iframe width="600" height="360" src="//www.youtube.com/embed/vPF3Ctscvxc?rel=0" frameborder="0" allowfullscreen></iframe></center><br>
 
-
 
-
</div>
 
-
</div>
 
<div class="row">
<div class="row">
<div class="nine columns"><p id="5"></p>
<div class="nine columns"><p id="5"></p>
Line 453: Line 467:
<div class="nine columns"><p id="6"></p>
<div class="nine columns"><p id="6"></p>
-
<h3>Downloads Link</h3>
+
<h3>Download Links</h3>
-
<i>Right-click and click "Save Link as.." on the link of items that you want to download</i>
+
<i>Right-click and click "Save link as..." on the link to items that you want to download.</i>
<br><br>
<br><br>
<a href="https://static.igem.org/mediawiki/2013/c/c8/Interview_Appendix_-_Prof._Yu.pdf">Prof. Yu's Interview Script (PDF)</a>
<a href="https://static.igem.org/mediawiki/2013/c/c8/Interview_Appendix_-_Prof._Yu.pdf">Prof. Yu's Interview Script (PDF)</a>

Latest revision as of 12:56, 28 October 2013

Prof. Albert Yu

Overview

Professor Albert Yu is the chairman of the Hong Kong Biotechnology Organization (HKBIO), and also a professor of the Department of Neurobiology of Peking University, China. As an entrepreneur and a scientist, Prof. Yu gave us realistic insights to our project. Meeting Prof. Yu helped us to evaluate our project beyond the laboratory environment and to think about its possible future application as a biotechnology product. Towards the end of the interview, we also talked about the bioethics and biosafety issues regarding synthetic biology.

Main Discussion

Prof. Yu mentioned that our project is a small step and that we have a long way to go to apply our project as a commercial biotechnology product. He told us that because we are trying to insert genes into a human body, we need to be very careful with concluding how our project could be realistically applied in the future. Inserting genes into a human body can create novel metabolism properties that could lead to side effects. Also, because the general public considers obesity less harmful, people might be reluctant to sign up for invasive treatment if they believe a less invasive means such as exercising can solve the problem. He also encouraged us to look into other plant genes that could be used to cure fatal diseases.

We also discussed about issues on biosafety and bioethics. Prof. Yu said that we need to be responsible scientists and utilize research to improve human life. He also mentioned that to produce a bioproduct, it is very important to consider the ethical issues of the project from the very start.

Conclusion

The interview with Professor Albert Yu helped us to realize the social environment our project would encounter, and the barriers that come with it. The interview also showed that more in-depth consideration of our project’s future application is necessary if we want to see it utilized as a safe bioproduct.

Pictures


Download Links

Right-click and click "Save link as..." on the link to items that you want to download.

Prof. Yu's Interview Script (PDF)

Retrieved from "http://2013.igem.org/Team:Hong_Kong_HKUST/hp/interview/yu"